Efficacy and prognosis of temozolomide combined with IMRT radiotherapy in patients with malignant glioma after surgery
Objective To evaluate the efficacy and prognosis of temozolomide combined with intensity-modulated radiation therapy(IMRT)in patients with malignant glioma after surgery.Methods A retrospective analysis of clinical data from 89 patients with malignant glioma treated from January 2018 to January 2021 at the Oncology Department of Affiliated People's Hospital of Jiangsu University was conducted.Patients were divided into a control group of 44 patients receiving IMRT alone and a treatment group of 45 patients receiving temozolomide combined with IMRT.The short-term therapeutic effects,quality of life scores before treatment and after four cycles of treatment[using the Quality of Life Questionnaire(QLQ-C30)],and the 1-year,2-year,and 3-year survival rates were compared between the two groups.Adverse reactions in the treatment group were observed.Results The objective response rate(ORR)and disease control rate(DCR)were 43.2％(19/44)and 86.4％(38/44)in the control group,compared with 66.7％(30/45)and 97.8％(44/45)in the treatment group.Both the ORR and DCR were significantly higher in the treatment group than in the control group(ORR:x2=5.42,P=0.020;DCR:x2=4.00,P=0.046).In the treatment group,7 patients experienced Grade Ⅰ-Ⅱ adverse reactions,including anemia,thrombocytopenia,fatigue,rash,gastrointestinal reactions,and myelosuppression.Two patients had Grade Ⅲ-Ⅳ adverse reactions,including gastrointestinal reactions and myelosuppression which improved after symptomatic treatment,and both patients were able to tolerate the treatment.No patient discontinued treatment due to adverse reactions.After four treatment cycles,the scores in all dimensions of the QLQ-C30 questionnaire were significantly higher in the treatment group than in the control group(P＜0.05).The 1-year,2-year,and 3-year survival rates in the treatment group were 77.8％,40.0％,and 24.4％,respectively,which were significantly higher than those in the control group(45.5％,22.7％,and 11.4％,P=0.002).Conclusion Temozolomide combined with IMRT demonstrates superior therapeutic effects in post-surgery malignant glioma patients,significantly improving the ORR,DCR,quality of life,and survival rates,with a low incidence of adverse reactions.
NETL
NSTL
万方数据
